Author Archives: Cindy Affandi

Cilcare Completes 40m Series A

BIOTECH

Cilcare completes a €40M series A
December 5, 2024

The funds will support two Phase 2a clinical trials for the drug candidate CIL001, targeting...

Doron Therapeutics 11m Series A Osteoporosis Drug Phase 3 Clinical Study

BIOTECH

Doron Therapeutics Raises $11M Series A to Progress Biologic Regenerative Osteoarthritis Drug into Phase 3 Clinical Studies
November 25, 2024

CHAPEL HILL, NC / ACCESSWIRE / November 25, 2024 / Doron Therapeutics, a clinical-stage biotech company...

Obviohealth Richard Watkins Chief Revenue Officer Transformation

BIOTECH

ObvioHealth Welcomes Richard Watkins as Chief Revenue Officer at a Pivotal Moment of Transformation
October 16, 2024

Experienced Sales Leader to Drive Revenue Growth as ObvioHealth Transitions to Enterprise Solutions NEW YORK, Oct....

Obviohealth Appointment Nicholas Campbell 2024

DIGITAL CLINICAL SOLUTION

ObvioHealth Announces the Appointment of Nicholas Campbell to Its Board of Directors
October 10, 2024

NEW YORK, Oct. 10, 2024 /PRNewswire/ — ObvioHealth, a leading digital health company revolutionizing clinical trial...

Pulsesight Therapeutics Presents Pst 611 Ever Congress 2024

BIOTECH

PulseSight Therapeutics to Present Data on PST-611 at EVER Congress 2024
October 7, 2024

PARIS, Oct. 07, 2024 (GLOBE NEWSWIRE) — PulseSight Therapeutics SAS, an ophthalmology biotech company developing...

This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.
Accept